Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

1.6K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.6K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.0K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.0K
Dementia01:30

Dementia

584
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
584
Cholinergic Neurons: Neurotransmission01:23

Cholinergic Neurons: Neurotransmission

5.5K
Cholinergic neurotransmission involves the synthesis and the release of acetylcholine (ACh) in order to transmit nerve impulses across the synapse. The process begins with the synthesis of acetyl CoA, a precursor for ACh, from ATP, acetate, and coenzyme A in the mitochondria. Choline, another vital precursor, is transported inside the neuron through choline transporters, including high-affinity choline transporter CHT1, low-affinity choline transporter CTL1, and lower-affinity choline...
5.5K
Cholinergic Receptors: Nicotinic01:15

Cholinergic Receptors: Nicotinic

5.9K
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
5.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bridging the gap: estimates of undetected dementia in Brazil.

Age and ageing·2026
Same author

Diagnostic accuracy of the Multicultural Cognitive Examination (MCE) for detection of MCI and dementia in a diverse international cohort.

The Clinical neuropsychologist·2026
Same author

Public Health.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Structural brain changes in people with dementia receiving Cognitive Stimulation Therapy: Preliminary findings.

International journal of clinical and health psychology : IJCHP·2025
Same author

Revised Diagnostic Criteria for Vascular Cognitive Impairment and Dementia-The VasCog-2-WSO Criteria.

JAMA neurology·2025
Same author

The potential for dementia prevention in Brazil: a population attributable fraction calculation for 14 modifiable risk factors.

Lancet regional health. Americas·2025

Related Experiment Video

Updated: Feb 17, 2026

Author Spotlight: Modeling Vascular Contributions to Alzheimer's Disease in Transgenic Mice
04:29

Author Spotlight: Modeling Vascular Contributions to Alzheimer's Disease in Transgenic Mice

Published on: May 17, 2024

1.2K

Vascular dementia and the cholinergic pathways.

Eliasz Engelhardt1, Denise Madeira Moreira2, Jerson Laks3

  • 1MD, PhD, Cognitive and Behavioral Neurology Unit-INDC/UFRJ.

Dementia & Neuropsychologia
|December 8, 2017
PubMed
Summary

Understanding vascular dementia requires knowing brain anatomy and cholinergic pathways. Strategic vascular lesions impacting these pathways cause cognitive decline, guiding new therapeutic targets.

Keywords:
anatomycholinergic fiberscognitive impairmentvascular dementia

More Related Videos

Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

22.4K
An Alternative Approach to Study Primary Events in Neurodegeneration Using Ex Vivo Rat Brain Slices
07:57

An Alternative Approach to Study Primary Events in Neurodegeneration Using Ex Vivo Rat Brain Slices

Published on: April 11, 2018

7.4K

Related Experiment Videos

Last Updated: Feb 17, 2026

Author Spotlight: Modeling Vascular Contributions to Alzheimer's Disease in Transgenic Mice
04:29

Author Spotlight: Modeling Vascular Contributions to Alzheimer's Disease in Transgenic Mice

Published on: May 17, 2024

1.2K
Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

22.4K
An Alternative Approach to Study Primary Events in Neurodegeneration Using Ex Vivo Rat Brain Slices
07:57

An Alternative Approach to Study Primary Events in Neurodegeneration Using Ex Vivo Rat Brain Slices

Published on: April 11, 2018

7.4K

Area of Science:

  • Neuroscience
  • Cerebrovascular Medicine
  • Cognitive Neurology

Background:

  • Vascular cognitive impairment/dementia (VCI/VD) is prevalent, with significant therapeutic potential.
  • Understanding cerebral vascular territories aids in classifying VCI/VD clinical presentations.
  • The central cholinergic system modulates cognition, behavior, and cerebral blood flow.

Purpose of the Study:

  • To correlate cerebral vascular anatomy with cholinergic pathway trajectories.
  • To identify strategic lesion sites impacting cholinergic function in VCI/VD.
  • To provide a foundation for treatments enhancing cholinergic activity.

Main Methods:

  • Review of neuroanatomical studies on basal prosencephalon nuclei and projections.
  • Analysis of cerebral vascular distribution maps.
  • Integration of vascular and cholinergic pathway data.

Main Results:

  • Established anatomical knowledge of cholinergic pathways and their vascular supply.
  • Identified critical vascular territories where lesions disrupt cholinergic projections.
  • Demonstrated that vascular lesions lead to localized cholinergic hypofunction.

Conclusions:

  • Vascular lesions strategically located relative to cholinergic pathways cause denervation and hypofunction.
  • This anatomical understanding enhances evaluation of lesion sites in VCI/VD.
  • Provides a basis for developing targeted therapies to boost cholinergic activity for VCI/VD treatment.